News

FDA approves vepdegestrant for ER-positive, HER2-negative breast cancer. Learn key efficacy data, safety risks, and nursing care considerations.

Phase 3 MagnetisMM-5 trial data in multiple myeloma highlight progression-free survival gains and key safety considerations for oncology nurses.

Paget disease of the breast: key signs, diagnosis, and treatment strategies oncology nurses should know to support early detection and patient care.

Oncology nurse practitioners discuss CD38-based frontline therapy for newly diagnosed multiple myeloma, including Dara-VRd efficacy, AE management, and subcutaneous administration strategies.

Oncology nurses play key role in guiding patients with non-small cell lung cancer on KRAS therapies and emerging options.

FDA accepts Zanidatamab combo sBLA for HER2+ gastroesophageal cancer, showing improved outcomes in HERIZON-GEA-01 trial with priority review underway.

Catherine Boyles, RN, provides an overview of fertility preservation in young cancer patients and the role of oncology nurses.

Consistent assessment and follow-up help manage low-grade irAEs, with continued monitoring and coordination supporting long-term toxicity care.

Workforce shortages, delayed diagnoses, and systemic barriers continue to limit cancer care delivery in low-resource settings, experts report.

Ozekibart plus FOLFIRI demonstrated a 20% response rate and 5.5-month progression-free survival in heavily pretreated colorectal cancer.

LITESPARK-012 failed to improve OS or PFS in advanced renal cell carcinoma, reinforcing pembrolizumab plus lenvatinib as a first-line standard.

FDA grants Priority Review to enfortumab vedotin plus pembrolizumab in MIBC, showing improved survival and reduced recurrence risk in phase 3 EV-304 trial.

Anjali Albanese spoke about the unique emotional and psychosocial challenges faced by younger adults following a cancer diagnosis.

At SGO 2026, the BEHOLD-1 trial revealed a 62% ORR for mocertatug rezetecan in PROC, offering a manageable new ADC option for oncology nurses to track.

1INSPIRE data at SGO 2026 confirms frontline niraparib (Zejula) has a manageable safety profile with low discontinuation rates in ovarian cancer.

Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact life expectancy.

Data at SGO 2026 showed gynecologic cancer survivors face high rates of untreated LUTS and missed radiation cystitis diagnoses after treatment.

Dr. Michael Wong of Roswell Park explains why melanoma survivors must prioritize skin barrier protection over tanning to prevent further UV injury.

Dr. Don Dizon discusses why early fertility referral and avoiding clinical assumptions are vital for young breast cancer patients at diagnosis.

Alembic Pharmaceuticals receives FDA approval for Methotrexate Injection for patients with cancer.

The OPTIMAL trial shows oral DHP107 matches IV paclitaxel efficacy in HER2-negative metastatic breast cancer with lower rates of neuropathy.

Phase 3 trial results show letrozole monotherapy is not noninferior to chemotherapy followed by hormone therapy for patients with advanced LGSOC.

Phase 2 GOG 3039 trial data from SGO 2026 shows abemaciclib and letrozole improved PFS in patients with advanced or recurrent endometrial carcinoma.

Explore how Jessica MacIntyre, ONS President, is transforming oncology care through APP fellowships, a new skin toxicity database for diverse skin tones, and innovative survivorship models at Sylvester Comprehensive Cancer Center.

New phase 2 data confirms the Avmapki Fakzynja Co-pack offers lasting efficacy and stable safety for patients with recurrent KRAS-mutated LGSOC.

Phase 3 ROSELLA data shows relacorilant and nab-paclitaxel reduced death risk by 35% in platinum-resistant ovarian cancer, a new preferred treatment.